Up-date Management of Non Responder to Clomiphene Citrate in Polycystic Ovary Syndrome

Kobe Journal of Medical Sciences

Volumn 49, Issue 3-4, 2003, Pages 59-73

  Amin, Magdy ^a   Abdel Kareem, Osman ^a   Takekida, Shigeki ^b   Moriyama, Toshitake ^b   El Aal, Gada Abd ^a   Maruo, Takeshi ^b  

^a Sohag University   (Egypt)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hyperinsulinemia; Insulin sensitizing agents; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; BROMOCRIPTINE; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; CONTRACEPTIVE AGENT; DEXAMETHASONE; FOLLITROPIN; GONADORELIN AGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; INOSITOL DERIVATIVE; INSULIN; INSULIN SENSITIZING AGENT; LUTEINIZING HORMONE; METFORMIN; RECOMBINANT DNA; TROGLITAZONE; UROFOLLITROPIN; VASCULOTROPIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; CLOMIFENE; INOSITOL PHOSPHATE; INOSITOL PHOSPHATE GLYCAN; POLYSACCHARIDE;

ACHONDROPLASIA; ADJUVANT THERAPY; ANDROGEN RELEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; FEMALE INFERTILITY; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTIC ACIDOSIS; LAPAROSCOPIC SURGERY; LIVER NECROSIS; MEGALOBLASTIC ANEMIA; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOGENESIS; PATHOPHYSIOLOGY; SHORT SURVEY; SIDE EFFECT; STOMACH PAIN; TERATOGENESIS; ANOVULATION; DRUG COMBINATION; DRUG RESISTANCE; FEMALE; GYNECOLOGIC SURGERY; HYPERINSULINISM; LAPAROSCOPY; OVARY; REVIEW; TREATMENT FAILURE;

ANOVULATION; CHROMANS; CLOMIPHENE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INOSITOL PHOSPHATES; LAPAROSCOPY; METFORMIN; OVARY; POLYCYSTIC OVARY SYNDROME; POLYSACCHARIDES; THIAZOLIDINEDIONES; TREATMENT FAILURE;

EID: 1842666672     PISSN: 00232513     EISSN: 18830498     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (100)

1. Franks, J., Adams, H., and Mason, D. 1995. Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol 12: 603-633
2. Pritts, E. 2002. Treatment of infertile patients with polycystic ovary syndrome. Obstet Gynecol Survey 57: 587-596.
3. Cynthia, M., Farquhar, F., Karen, R., Guy, G., and Franzcog. P. 2002. Randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate resistant polycystic ovary syndrome. Fertil Steril 78: 404-411.
4. Kelly, L., and Adashi, Y. 1987. Ovulation Induction. Obstet Gynecol Clin North Amer 14: 831-836.
5. Mitwally, M., Selma, F., and Witchel. F. 2002. Troglitazone: A possible Modulator of ovarian steroidogenesis. J Soc Gynecol Investigation 9: 163-167.
6. David, T., Vandermolen, S., Ratts, S., Dale, W., Stovaland, J., and Nestler, E. 2001. Metformin increases the ovulatory rate from clomiphene citrate inpatients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Ferti Steril 75: 310-315.
7. Costello, M., and Eden, A. 2003. A systemic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 79: 1-13.
8. Mitwally, M., Kuscu, K., and Yalcinkaya, T. 1999. High ovulation rate with the use of troglitazone in clomiphene resistant women with polycystic ovary syndrome. Human. Reproduction 14: 2700-2703.
9. Stein IF., and Leventhal. ML. 1935. Amenorrhea associated with bilateral polycystic ovaries. Am Obstet Gynecol 29: 181-191.
10. Speroff, L., Glass, R., and Kase. G. 1999. In: Speroff L., Glass R., Kase. G. (eds.). Clinical Gynecology Endocrinology and Infertility, sixth edition (Williams & Wilkins Baltimore Maryland). Anovulation and the polycystic ovary 487-521.
11. Dunaif, A. 1994. Molecular mechanism of insulin resistance in polycystic ovary syndrome. Semin Reprod Endocrinol 12: 15-20.
12. Nestler, E., Powers, L., Matt, W., Steingold, K., Plymate, R., and Rittmaster. S. 1991. Direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrine. Metab 72: 83-89.
13. Utiger, R. 1996. Insulin and polycystic ovary syndrome. N Engl J Med 335: 657-658.
14. Parsanezhad, M., Alborzi, A., Zarei, A., Dehbashi, S., and Omrani. G. 2001. Insulin resistance in clomiphene responder with polycystic ovarian disease and therapeutic effect of metformin. Internt J Gyn Obst 75: 43-50.
15. Barbieri, R. 1992. Effect of insulin in polycystic ovary syndrome. In: Dunaif, A., Givens, J., Haseltine, F., and Merriam. G., editors. Polycystic ovary syndrome. Boston: Blackwell 249-261.
16. Taylor, E. 1998. Understanding the under lying metabolic abnormalities of polycystic ovary syndrome and their implication. Am J Obst Gynecol 179: 101-109.
17. De Leo, V., la Marca, A., Morgante, G., Ciotta, L., Mencaglia, L., Cianer, L., and Petraglia. L. 2000. Clomiphene citrate increase insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I withoud correcting insulin resistance associated with polycystic ovary syndrome. Human Reprod 15: 2302-2305.
18. Stadtmauer, A., Laurel, C., and Sergio. O. 2002. Should patients with PCOS be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome beyond ovulation induction. Human Reprod 17: 3016-3025.
19. Poretsky, L., Cataldo, A., Rosenwaks, Z., and Giudice. L. 1999. The insulin related ovarian regulatory system in health and disease. Endocrine Review 20: 535-882.
20. Dunaif, A. 1997. Insulin resistance and polycystic ovary syndrome mechanism and implication for pathogenesis. Endocrin Review 18: 774-800.
21. Christof, S., Rudiger, H., Thilo, S., Hans, S., Manfred, M., and Georg. B. 2002. Circulating ghrelin leveles in patients with polycystic ovary syndrome. Clin. Endocrinol Metab 87: 4607-4610.
22. Pagotto, U., Gambineri, A., Vicnnati, V., Heiman, ML., Tschop, M., and Pasquali. R. 2002. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrin Metab 87: 5625-5629.
23. Lee, A., Christenson, K., Patton, P., Burry, K., and Stouffer. L. 1997. Vascular endothelial growth factor production by human luteinized granulose cells in vitro. Human Reprod 12: 2756-2761.
24. Agrawal, R., Conway, G., Sladkevicius, P., Tan, L., and Jacobs. H. 1998. Serum vascular endothelial growth factor and doppler flow velocities in invitro fertilization: Relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril 70: 651-658.
25. Amano, S., Miyamoto, K., Garland, R., Keough, k., and Qin. W. 1999. Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol 40: 3281-3286.
26. Seibel, M. 1984. Toward understanding the pathophysiology and treatment of polycystic ovary syndrome. Semin. Reprod Endocrinol 2: 297-301.
27. Dunaif, A., Graf, M., Mandeli, J., Laumas, V., and Dobrjansky. A. 1987. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin. Endocrinol Metab 65: 499-507.
28. Dunaif, A., Green, G., Futterweit, W., and Dobrjansky. A. 1990. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 70: 699-704.
29. Norman, J., Davies, J., Lord, J., and Moran. J. 2002, The role of life style modification in polycystic ovary syndrome. J Endocrinol Metabolism 13: 251-257.
30. Guzic, E., Wing, R., and Smith. D. 1994. Endocrine consequences of weight loss in obese hyperandrogenic women. Fertil Steril 61: 598-602.
31. Conway, G.S., Agrawal, R., and Btteridge. D. 1992. Risk factors for coronary disease in lean and obese women with PCOS. J Clin Endocrinol 37: 119-121,
32. Kiddy, D., Hamilton, O., Bush, A., Short, f., Anyaoku, V., and Reed. M. 1992. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovarian syndrome. J Clin Endocrinol 36: 105-108.
33. Taskin, O., Yalcinogl, I., Kafkasli, A., Bura, F., and Ozekici. U. 1996, Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease. Fertil Steril 65: 1115-1118.
34. Acien, P., Mauri, M., and Gutierez. M. 1997. Clinical and hormonal effects of the combination gondotrophin-relesing hormone agonist plus oral contraceptive pills containing ethinyloestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandogcnism. Hum Reprod 12: 423-430.
35. Lobo, A., Granger, R., Davjan, V. and Mishell. R. 1982. An extended regimen of clomiphene citrate in women unresponsive to standard therapy. Fertil Steril 37: 762-766.
36. Padilla, L., Person, K., McDonough, G., and Reindollar. H. 1985. The efficacy of bromocriptine in patients with ovulatory dysfunction and normo-prolactinemeic galactorrhea. Fertil Steril 44: 695-698.
37. Porcile, A., Gallardo, E., and Vengas. E. 1990. Normoprolactinemic anovulation nonersponsive to clomiphene citrate: ovulation induction with bromocriptine. Fertil Steril 53: 50-53.
38. Cuzick, S. 1986. Bromocriptine therapy in normoprolactinemic women with unexplained infertility and galactorrhea. Fertil Steril 46: 1026-1029.
39. Phipps, R. 2001. Polycystic ovary syndrome and ovulation induction. Obstet Gynecol Clin North Am 28: 165-182.
40. Kettle, L., and Erickson. G. 1994. Basic and clinical concepts in ovulation induction. Advances in Obstetrics and Gynecology 1: 211-217.
41. Anderson, E., Cragun, M., Chang, J., Stanczk, Z., and Lobo. A. 1989. A pharmacological comparison of human urinary follicle stimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome. Fertil Steril 52: 216-220.
42. Mizunuma, H., Takagi, T., Yamada, K., Andoh, K., Ibuki, Y., and Igarashi. M. 1991. Ovulation induction by step-down administration of purified urinary follicle-stimulating hormone in patients with polycystic ovary syndrome. Fertil Steril 55: 11195-11206.
43. Homburg, T., and Ben-Rafael. Z. 1995. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovarian disease. Fertil Steril 63: 729-733.
44. Balasch, J., Franciso, F., Montserrat, C., Bienvendiop, P., Joana, P., and Juan. V. Human. Reprod. 2001. Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovary syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Human Reprod 16: 652-656.
45. Polson, DW., Mason, AD., Kiddy, DS., Winston, RM., Margara, R., and Franks. S. 1989. Low-dose follicle-stimulating hormone in the treatment of polycystic ovary syndrome: Acomparison of plusatile subcutaneous with daily intramuscular therapy. Br J Obstetric Gynecol 96: 746-748.
46. Andoh, K., Mizunuma, H., Liu, X., Kamijo, T., and Yamada. K. 1998. A comparative study of fixed-dose, step-down, and low dose step-up regimens of human menopausal gonadotropin for patients with polycystic ovary syndrome. Fertil Steril 70: 840-846.
47. Ben-Rafael, Z., Mashiach, T., Oeisner, G., and Farine. D. 1981. Spontaneous pregnancy and its outcome after human menopausal gonadotropin/human chorionic gonadotropin-induced pregnancy. Fertil Steril 36: 560-565.
48. Prevost, R. 1988. Recombinant follicle-stimulation hormone: new biotechnology for infertility. Pharmacotherapy 18: 1001-1010.
49. Aboulghar, A., Mansour, T., Serour, L., Amin, M., Sattar, A., and Ellater. E. 1996. Recombinant follicle-stimulating hormone in the treatment of patients with history of sever hyperstimulation syndrome. Fertil Steril 66: 757-760.
50. David, R. 2002. Vascular endothelial growth factor polycystic ovary syndrome, and ovarian hyperstimulation syndrome. Fertil Steril 78: 1170-1171.
51. Agrwal, R., Jacobs, H., Payne, N., and Conway. G. 2002. Concentration of vascular endothelial growth factor released by cultured human luteinized granulose cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril 78: 1170-1171.
52. Raoul, O. 2003. Prediction of ovarian hyperstimulation syndrome challenging the estadiol mythos. Hum Reprod 18: 665-667.
53. Sher, G., Salen, R., Feinman, M., Dodge, S., Zouves, C., and Knutzen. V. 1993. Eliminating the risk of life-endangering complication following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obstet Gynecol 81: 1009-1013.
54. Rizk, B., and Aboulghar. A. 1994. Complications of reproduction technologies. Am. J. Obstet Gynecol 9: 1235-1238.
55. Spadoni, L., R, Cox, W., and Smith. C. 1986. Use of human Menopausal Gonadotropin for the induction of ovulation. Am J Obstet Gynecol 120: 988-1001.
56. Yudin, H., Asztalos, V., and Jefferies. A. 2001. The management and out come of high order multifetal pregnancies. Obstetric neonatal and follow up data-twin research 4: 4-11.
57. Rosa, T., Pedro, N., Buenaventura, C., Rosario, B., Martiz, F., and Balasch. J. 2001. Risk factors for high order multiple implantation after ovarian stimulation with gonadotropins: evidences from a large series of 1870 consecutive pregnancies in single center. Human Reprod 16: 2124-2129.
58. Weiss, G., Goldsmith, T., Sachder, R., Hagen, V., and Lederer. K. 1993. Elevated first-trimester serum relaxin concentrations in pregnant women following ovarian stimulation predicts prematurity risk and preterm delivery. Obstet Gynecol 82: 821-825.
59. Nestler, J., Stovall, D., Akhter, S., Luorno, M., and Jakubowicz, D. 2002. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2: 209-215.
60. Legro, S. 1998. Polycystic Ovary Syndrome: Current and future treatment paradigms. Am J Obst Gynecol 79: 101-104.
61. Marca, A., Morgante, G., Palumbo, M., Cianci, A., Petraglia, T., and De Leo. V. 2002. Insulin-lowering treatment reduces aromatase activity response to follicle stimulating hormone in women with polycystic ovary syndrome. Ferti Steril 78: 1234-1239.
62. Marca, A., Egbe, T., Morgante, G., Paglia, T., Ciani, A., and De Leo. V. 2000. Metformin treatment reduces ovarian cytochrome P-450c 17 response to human chorionic gonadotropin in women with insulin resistance-related polycystic ovary syndrome. Human Reprod 15: 21-23.
63. Jakubowics, D., Seppala, M., Jakubowics, S., Otto, R., Rivas, A., Koistinen, H., Koistinen, R., and Nestler. J. 2001. Insulin reduction with metformin increase luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentration and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J. Clin. Endoc. Metab. 86: 1126-1133.
64. Sills, E., Perloe, M., and Palermo. G. 2000. Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Europian J Obst Gynecol 91: 135-141.
65. Homburg, R. 2002. Should patients with polycystic ovary syndrome be treated with metformin? A note of caution optimism. Human Reprod 17: 853-856.
66. Kandarakis, E., Kouli, C., Tsianateli, T., and Bergiele. A. 1998. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Europ J Endocrin 138: 269-274.
67. Ellis, A., Iliescu. E. 2001. Metformin-associated lactic acidosis in a low risk patient. Can J Clin Pharmacol 8: 104-106.
68. Kocak, M., Caliskan, E., Simsir, C., and Haberal. A. 2002. Metformin therapy improves ovulatory rates, cervical scores and pregnancy rates in clomiphene citerate-resistant women with polycystic ovary syndrome. Feril Steril 77: 101-106.
69. Vandermolen, D., Ratts, V., Evans, W., Stovall, D., Kauma, S., and Nestler. J. 2001. Metformin increase the ovulatory rate and pregnancy rate in patient with polycystic ovary syndrome. Fertil Steril 75: 310-315.
70. De Leo, V., la Marca, A., Ditto, A., Morgante, G., and Cianci. A. 1999. Effect of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 72: 282-285.
71. Stadtmauer, A., Toma, K., Riehl, M., and Tablert. M. 2001. Metformin treatment of patients with poycystic ovary syndrome undergoing in-vitro fertilization improves outcomes and is associated with modulation of the insulin like growth factors. Fertil Steril 75: 505-509.
72. Seli, E., and Duleba. J. 2002. Should patients with polycystic ovary syndrome treated with metformin? Human Reprod 17: 2230-2236.
73. Glueck, J., Phillips, H., Cammeron, D., Sieve-Smith, L., and Wang. P. 2001. Continuing metformin through through pregnancy in women with polycystic ovary syndrome to savely reduce first trimester pregnancy loss: apilot study. Fertil Steril 75: 46-49.
74. Ehrman, R., Schneider, J., and Sobel. E. 1997. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with PCOS. J Clin Endocrinol Metab 82: 2108-2116.
75. Dunaif, A., Scott, D., and Finegood. D. 1996. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in PCOS. J Clin. Endocrinol Metab 81: 3299-3306.
76. Salteil, J., and Olefsky. J. 1996. Thiazolidindiones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669.
77. Lehman, M., Moor, I., Oliver, A., Wilkison, W., and Kliwer. A. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activator receptor gamma(PPAR-gamma). J Biol Chem 270: 1295-1296.
78. Mitwally, M., Witchel, S., and Casper. R. 2002. Troglitazone: Apossible modulator of ovarian steroidogenesis. J Soc Gynecol Investig 9: 163-167.
79. Aziz, R., Ehramn, D., and Lergo. S. 2001. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter Double blind, placebo-controlled trial. J Clin. Endocrinol Metab 4: 1626-1632.
80. Nestler, J., Jakubowicz, J., and Iurono, J. 2000. Role of inositophosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr. Endocrinol. Metab 5: 1295-1298.
81. nd annual meeting of the Endocrine Society, San Diego, CA.
82. Mio, Y., Toda, T., Tanikawa, M., Terado, H., Harada, T., and Terakawa. N. 1991. Transvaginal ultrasound-guided follicular aspiration in the management of anovulatory infertility associated with polycystic ovaries. Fertil Steril 56: 1060-1065.
83. Farquhar, C., Vandekerckhove, P., Arnot, M., and Lilford. R. 2001. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane library 4: 12-16
84. Balen, H., and Jacobs. S. 1994. A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with polycystic ovary syndrome. Fertil Steril 62: 921-925.
85. Farhi, J., Soule, S., and Jacobs, S. 1995. Effect of laparoscopic ovarian electrocautery on ovarian response and outcome of treatment with gonadotropins in clomiphene citrate-resistant patients with PCOS. Fertil Steril 64: 930-935.
86. Cohen, B. 1989. Laser laparoscopy for polycytic ovaries. Fertil Steril 52: 167-170.
87. Lockwood, M., Muttukrishna, S., Groome, P., and Matthews. R. 1998. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergences of dominant follicle. J Clin. Endocrinol Metab 83: 1730-1735.
88. Gomel, V., and Wang. I. 1994. Laparoscopic surgery for infertility therapy. Current Openion Obstet Gynecol 6: 141-148.
89. Gjonnaess, H. 1984. Polycystic ovarian disease treated by ovarian electrocautery through the laparoscope. Fertil Steril 41: 20-24.
90. Ferraretti, A., Gianaroli, L., Maria, C., Iammarrone, E., Felicia, E., and Fortini. D. 2001. Clinical outcome of assisted reproduction technologies In patients with polycystic ovary syndrome. Fertil Sertil 76: 812-816.
91. Heylen, S., Puttemans, P., and Brosens. I. 1995. Polycystic ovarian disease treated by laparoscopic argon laser capsule drilling: comparison of vaporization versus perforation technique. Hum Repord 9: 1038-1042.
92. Cohen, J. 1995. Laparoscopic procedures for treatment of infertility related to polycystic ovarian syndrome. Fertil Steril 64: 353-358.
93. El-Helow, A., Ghorab, M., and El Attar. E. 1996. Surgical induction of ovulation in women with polycystic ovary syndrome: A critical analysis of published data. J Middle. East Fertility Society 1: 101-115.
94. Kovacs, G. 1993. Endoscopic surgical approach to the treatment of anovulation due to polycystic ovary syndrome ovarian drilling. In: Endoscopic surgery for gynecologists. Edited by C Sutton and M Diamand, WB Saunders Company LTD 147-153.
95. Gjonnaess, H., and Norman. N. 1987. Endocrine effects of ovarian electrocautery in patients with polycystic ovarian disease. Br J Obstet Gynaecol 94: 774-783.
96. Sakata, M., Tasaka, K., and Kurachi. H. 1990. Changes of bioactive luteinizing hormone after laparoscopic ovarian cautery in patients with polycystic ovarian syndrome. Fertil Steril 53: 610-613.
97. Amer, S., Goplan, V., Li, T., and Cooke. I. 2002. Long term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. Hum Reprod 17. 2851/2857.
98. Neather, J., Fischer, R., and Weise. C. 1993. Laparoscopic electrocoagulation of the ovarian surface in infertile patients with polycystic ovarian disease. Fertil Steril 60: 88-94.
99. Armar, A., and Lachelin. C. 1993. Laparoscopic ovarian diathermy: an effective treatment for anti-estrogen resistant ovulatory infertility in women with the polycystic ovary syndrome. Br J Obstet Gynaecol 100: 161-164.
100. Dabirashrafi, H., Mohamed, K., and Behjatnia. Y. 1991. Adhesion formation after ovarian electrocauterization on patients with polycystic ovarian syndrome. Fertil Steril 55: 1200-1201.